Contemporary treatment of metastatic renal cell carcinoma

Wiechno, Paweł; Kucharz, Jakub; Sadowska, Małgorzata; Michalski, Wojciech; Sikora-Kupis, Bożena; Jońska-Gmyrek, Joanna; Poniatowska, Grażyna; Nietupski, Karol; Ossoliński, Krzysztof; Demkow, Tomasz

doi:10.1007/s12032-018-1217-1

Cited by 49 publications

(49 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renal cell carcinoma (RCC) originates from the renal parenchyma and is the most common subtype of kidney cancer ( 1 ). According to 2018 GLOBOCAN data, RCC accounts for up to 2.4% of all cancer cases, with an estimated 338,000 patients diagnosed globally each year ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

et al. 2020

View full text Add to dashboard Cite

Substantial research attention has been directed at exploring the mechanisms and treatment of renal cell carcinoma (RCC). Indeed, the association between inflammation and tumor phenotypes has been at the center of cancer research. Concomitant with research on the inflammation response and inflammatory molecules involved in RCC, new breakthroughs have emerged. A large body of knowledge now shows that treatments targeting inflammation and immunity in RCC provide substantial clinical benefits. Adequate analysis and a better understanding of the mechanisms of inflammatory factors in the occurrence and progression of RCC are highly desirable. Currently, numerous RCC treatments targeted at inflammation and immunotherapy are available. The current review describes in detail the link between inflammation and RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our patient initially underwent TTE, which revealed a mass in the right atrium, and a CT was ordered to look for possible causes of this mass. After the diagnosis of RCC is made, the patient should be evaluated for metastasis [ 8 ]. Tissue biopsy may also be beneficial to determine the subtype of RCC, which can help with prognosis and treatment [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Initial Presentation of Renal Cell Carcinoma as Heart Failure Secondary to Tumor-Thrombus Extension to the Right Atrium

Patel

Kumar

Kalavakunta

et al. 2021

Cureus

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) can invade locally through the renal vein and into the inferior vena cava (IVC) with tumor-thrombus formation reported in 5%-15% of patients. From the IVC, RCC can grow intravascularly and extend into the right atrium. We present a rare case with two uncommon findings: tumor-thrombus extension leading to a right atrial mass and initial presentation of RCC as heart failure. A 69-year-old woman presented with signs and symptoms of heart failure. Electrocardiogram was normal and the initial troponin level was mildly elevated to 0.09 ng/mL. Echocardiography revealed a dilated right atrium with a 6.9 cm x 3.8 cm echogenic mass consistent with a tumor impinging on the tricuspid valve leading to a functional stenosis. Computed tomography (CT) of the abdomen revealed a large right-sided renal mass with enlargement of the renal vein suggestive of tumor thrombus. Although the initial presentation of RCC with cardiac symptoms is surprising, this case highlights the importance of maintaining a comprehensive differential diagnosis. It also signifies the need for further imaging as not all atrial masses are cardiac tumors. Many other primary tumors -kidney, liver, lung, and thyroid -can directly invade or metastasize into the atrium by way of the vena cava.

show abstract

“…RCC is a common malignant tumor characterized by poor prognosis, late diagnosis, frequent recurrence and heterogeneity (1–3). The primary therapy for patients with RCC is surgical removal followed by chemotherapy or radiotherapy; however, traditional therapeutics have not improved the quality of life of patients with RCC (31,32). Therefore, there is a requirement for further investigation into RCC.…”

Section: Discussionmentioning

confidence: 99%

UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma

Peng

Kang

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a common malignant tumor globally. The overall survival of patients with RCC is poor; one important factor is tumor heterogeneity. Ubiquitin-conjugating enzyme E2T (UBE2T) has been reported to act as an oncogene in various types of cancer; however, its role in RCC has yet to be investigated. In the present study, UBE2T was demonstrated via reverse transcription-quantitative PCR analysis to be significantly upregulated in RCC samples and cell lines compared with in normal tissue and cells. Additionally, UBE2T expression was significantly associated with late tumor stage and high grade in patients with RCC, and patients with high UBE2T expression exhibited poor prognosis compared with patients with low expression. Following knockdown of UBE2T in 786-O cells using RNA interference technology, the proliferation and colony formation of cells were inhibited as determined by an MTT assay and crystal violet staining, respectively; however, the migration and invasion of 786-O cells were not affected, as determined by wound-healing assay and Transwell assays, respectively. Xenograft RCC tumor growth in vivo was also significantly suppressed. The expression levels of two mesenchymal cell markers, N-cadherin and vimentin, were reduced following UBE2T knockdown, whereas E-cadherin and fibronectin levels were increased as determined by western blotting, indicating that epithelial-mesenchymal transition was suppressed. In addition, the phosphorylation levels of PI3K, Akt and mTOR were notably decreased following UBE2T knockdown, but were increased when UBE2T was overexpressed. Wortmannin, an Akt inhibitor, reversed the UBE2T overexpression-induced increase in the phosphorylation of PI3K, Akt and mTOR. Similarly, the UBE2T overexpression-induced promotion of 786-O cell proliferation was also attenuated by wortmannin. In conclusion, UBE2T promoted the proliferation of RCC cells by regulating PI3K/Akt signaling, suggesting it may be a novel target for the treatment of patients with RCC.

show abstract

Contemporary treatment of metastatic renal cell carcinoma

Cited by 49 publications

References 61 publications

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

Initial Presentation of Renal Cell Carcinoma as Heart Failure Secondary to Tumor-Thrombus Extension to the Right Atrium

UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma

Contact Info

Product

Resources

About